Eli Lilly is the first pharmaceutical company to receive FDA approval for systemic treatment of severe, adult alopecia areata with JAK Inhibitor molecules. The medication, Olumiant (baricitinib), is taken orally once a day.
Two other pharmaceutical companies, Concert and Pfizer, are not far behind. Both will be seeking FDA approval for their treatments using JAKs at the conclusion of their clinical trials.
Concert’s trial is known as THRIVE AA-2.
Pfizer’s trial is known as ALLEGRO.